Sociedad Americana de Hirudoterapia

Bivalirudin in pediatric extracorporeal membrane oxygenation

Research article published in Current opinion in pediatrics (2022)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Narrative reviewDesarrollo de fármacosRyerson LM et al. · Current opinion in pediatrics, 2022

Abstract

PURPOSE OF REVIEW: This review summarizes the current literature surrounding the use of bivalirudin as an alternative anticoagulant for pediatric extracorporeal membrane oxygenation (ECMO) patients. RECENT FINDINGS: Recent single center studies describe that bivalirudin may be associated with decreased blood product transfusion, decreased cost and similar clinical outcomes for pediatric ECMO patients who have failed unfractionated heparin (UFH) anticoagulation. aPTT is the most common test to monitor bivalirudin but has several limitations. Other tests including dilute thrombin time (dTT) and viscoelastic assays are promising but more study is needed. Current evidence suggests that bivalirudin is a well tolerated and effective alternative anticoagulant for pediatric ECMO patients who have failed UFH anticoagulation but prospective studies are needed to confirm these results. SUMMARY: Bivalirudin is a promising alternative anticoagulant for pediatric ECMO patients who have failed UFH. Large prospective, multicenter studies are needed to confirm safety and efficacy.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleReview
Indexed MeSH termsAnticoagulantsChildExtracorporeal Membrane OxygenationHeparinHirudinsHumansPeptide FragmentsProspective StudiesRecombinant Proteins

Resumen

Bivalirudin in pediatric extracorporeal membrane oxygenation.

Por qué esto importa para la hirudoterapia

This review summarizes current literature on bivalirudin as an alternative anticoagulant for pediatric ECMO patients, particularly those who have failed unfractionated heparin (UFH). The review describes single-center studies suggesting bivalirudin may be associated with decreased blood product transfusion, decreased cost, and similar clinical outcomes, and discusses monitoring approaches including aPTT, dilute thrombin time, and viscoelastic assays. The abstract does not mention hirudin, leeches, or any leech-derived product, so no defensible connection to ASH's hirudotherapy domain can be drawn from this source. The authors conclude that large prospective multicenter studies are needed to confirm safety and efficacy.

Citación

Bivalirudin in pediatric extracorporeal membrane oxygenation

Ryerson LM et al. · Current opinion in pediatrics, 2022

Contexto clínico relacionado

Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.